Smoldering Multiple Myeloma

Thinking about what to do next?

DO SOMETHING “more than” WATCHING AND WAITING

Join the National Institutes of Health’s Research Study

Smoldering (“asymptomatic”) multiple myeloma (SMM) runs the risk of developing into multiple myeloma: a cancer of the plasma cells that presents with complications of bone fractures, low blood counts, high calcium levels and kidney problems. SMM is currently left untreated until multiple myeloma develops. Want to do more than watchful waiting? Scientists at the National Institutes of Health (NIH) National Cancer Institute (NCI) do!

One way is by testing a combination of cancer fighting drugs (Carfilzomib, Lenalidomide, and Dexamethasone) in the treatment of high-risk smoldering multiple myeloma. Come, partner with leading researchers in their efforts to test this combination for safety and effectiveness against high-risk smoldering multiple myeloma.

All study-related treatments, tests, and care provided at no cost

The NIH Clinical Center, America’s Research Hospital, is located in Bethesda, Maryland, on the Metro red line (Medical Center stop).

CONTACT
NIH Clinical Center
Office of Patient Recruitment
1-800-411-1222 or PRPL@cc.nih.gov
(Refer to 12-C-0107)
TTY for the deaf and hard of hearing:
1-866-411-1010
https://go.usa.gov/xUy7r

NIH...Turning Discoveries into Health®